Trial Profile
A Phase II, Randomized and Controlled Investigator Initiated Trial Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Outpatient Adult Subjects With Moderate Coronavirus Disease 2019 (COVID-19)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms CARE
- 05 May 2022 Status changed from active, no longer recruiting to completed.
- 20 Oct 2021 Results presented in the Senhwa Biosciences Media Release.
- 27 Sep 2021 Results published in the Senhwa Biosciences Media Release